Cefdinir for Oral Suspension USP — Class II drug recall D-1320-2019
Terminated recall by Lupin Pharmaceuticals Inc., reported 2019-06-05, distributed nationwide. Complaint received of metal piece identified in the product bottle prior to the reconstitution.
| Recall number | D-1320-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2019-05-23 |
| Classified | 2019-05-30 |
| Reported by FDA | 2019-06-05 |
| Terminated | 2020-10-22 |
| Distributed | Nationwide (US) |
| Quantity | 18,408 |
| Reason classes | foreign material |
| NDC | 68180-0722, 68180-0722-04, 68180-0722-05, 68180-0722-10, 68180-0722-20, 68180-0723, 68180-0723-04, 68180-0723-05, 68180-0723-10, 68180-0723-20 |
| Lot numbers | F802335 |
| Expiration dates | 2020-11-20 |
Product
Cefdinir for Oral Suspension USP, 250mg/5mL, Powder for oral suspension, 60 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 20201, Manufactured by: Lupin Limited, Mandideep 462 046 India. NDC 68180-723-20
Reason for recall
Complaint received of metal piece identified in the product bottle prior to the reconstitution.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1320-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.